Immix Biopharma, Inc. (IMMX)
IMMX moved a median of +0.43% 30 minutes after news, and +1.27% by the close. How IMMX actually reacts to news — the realized, point-in-time move the market made, measured across 216 labeled events over the last three years with zero look-ahead.
IMMX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.18% | 42% | 209 |
| 30-min | +0.43% | 54% | 215 |
| 60-min | +0.33% | 52% | 216 |
| to close | +1.27% | 59% | 214 |
| Middle 50% of IMMX reactions | -1.95% to +2.61% |
|---|---|
| Median reaction (30-min) | +0.43% |
| Measured reactions | 216 |
Half of all Immix Biopharma, Inc. news events land between -1.95% and +2.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMMX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 21 | -0.32% | 48% | -2.51% |
| Rating reiterations | 32 | -0.74% | 31% | -1.25% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IMMX ranks against every other measured name →
That’s how IMMX usually reacts — get an email when it moves on news →Email me when IMMX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMMX's baseline. Nothing else.
Recent IMMX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.93% | +4.33% | |
| Form 8-K Immix Biopharma, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -0.93% | -0.20% | |
| Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | -0.93% | -0.20% | |
| Form 8-K Immix Biopharma, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -1.38% | -9.06% | |
| Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory A | Press release | GlobeNewswire | -1.38% | -9.06% | |
| Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | -1.38% | -9.06% | |
| Form 10-Q Immix Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.90% | — | |
| IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | -1.76% | -5.08% | |
| Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.58% | +9.38% | |
| Form 8-K Immix Biopharma, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -12.00% | |
| Form 8-K Immix Biopharma, Inc. For: May 22 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | +4.77% | |
| Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | +1.57% | -0.56% | |
| Form 8-K Immix Biopharma, Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | -4.09% | |
| Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | Press release | GlobeNewswire | +4.09% | -4.09% | |
| Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock | Press release | GlobeNewswire | +4.09% | -4.09% | |
| Form 10-Q Immix Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.53% | +4.05% | |
| Immix Biopharma to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | +11.43% | |
| Form ARS Immix Biopharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.29% | +6.69% | |
| Form DEF 14A Immix Biopharma, Inc. For: Apr 06 | SEC filing · Form DEF | SEC EDGAR | -1.29% | +6.69% | |
| Form DEFA14A Immix Biopharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.29% | +6.69% | |
| Form 8-K Immix Biopharma, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +2.52% | +4.35% | |
| Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones | Press release | GlobeNewswire | +0.43% | +4.76% | |
| Form 10-K/A Immix Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.43% | +4.76% | |
| Form 10-K Immix Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.70% | +7.26% | |
| Form 8-K Immix Biopharma, Inc. For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +6.70% | +7.26% | |
| Form S-8 Immix Biopharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | +6.70% | +7.26% | |
| Immix Biopharma to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.66% | -1.33% | |
| Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 | Press release | GlobeNewswire | -1.85% | +3.02% | |
| Form EFFECT Immix Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.90% | +2.28% | |
| Form S-3 Immix Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -3.08% | -8.83% | |
| Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | +0.61% | +2.44% | |
| Form 8-K Immix Biopharma, Inc. For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | -1.53% | +4.77% | |
| At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis | Press release | GlobeNewswire | -1.53% | +4.77% | |
| Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -1.53% | +4.77% | |
| Form EFFECT Immix Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.74% | -1.49% | |
| Form 8-K Immix Biopharma, Inc. For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -1.16% | |
| Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch | Press release | GlobeNewswire | +1.53% | +14.11% | |
| Form 10-Q Immix Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.68% | -0.61% | |
| Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 | Press release | GlobeNewswire | -5.01% | -3.96% | |
| Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference | Press release | GlobeNewswire | -1.62% | +0.41% | |
| Form S-3 Immix Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.50% | +12.25% | |
| Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting | Press release | GlobeNewswire | +4.87% | +11.06% | |
| Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference | Press release | GlobeNewswire | -0.48% | +0.48% | |
| Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 | Press release | GlobeNewswire | +0.78% | +0.00% | |
| Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors | Press release | GlobeNewswire | +0.00% | +0.91% | |
| Form 8-K Immix Biopharma, Inc. For: Sep 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.70% | |
| Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang | Press release | GlobeNewswire | +0.00% | +2.70% | |
| Immix Biopharma to Present at the Stifel 2025 Healthcare Conference | Press release | GlobeNewswire | +0.30% | -2.33% | |
| Form 10-Q Immix Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.15% | -2.93% | |
| Immix Biopharma Announces Other Serious Diseases Strategy | Press release | GlobeNewswire | -4.17% | -5.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMMX section they belong to.
Where else IMMX is measured.
IMMX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immix Biopharma, Inc.'s median reaction calculated?
Every labeled IMMX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 216 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of IMMX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMMX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.